苏州普乐康医药科技

Pulekang Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, focused on developing innovative small molecule drugs for metabolic and endocrine disorders. The company's primary focus is on addressing high-prevalence conditions such as non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH). Its lead program, PLK-002, is a selective thyroid hormone receptor beta (THR-beta) agonist designed to improve lipid metabolism and reduce liver fat. Pulekang is supported by prominent venture capital firms and operates out of the Suzhou Industrial Park. The company aims to provide effective and safe therapeutic options for patients with chronic metabolic diseases through rigorous scientific research and clinical development.